Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Benoît Thomas P. Gilbert"'
Autor:
Benoît Thomas P. Gilbert, Céline Lamacchia, Lena Amend, Till Strowig, Emiliana Rodriguez, Gaby Palmer, Axel Finckh
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundThe pathogenesis of rheumatoid arthritis (RA) is believed to initiate at mucosal sites. The so-called ‘mucosal origin hypothesis of RA’ postulates an increased intestinal permeability before disease onset. Several biomarkers, including
Externí odkaz:
https://doaj.org/article/518112e8b70547f99398a2f77cb1bf2b
Autor:
Lena Amend, Benoît Thomas P. Gilbert, Penelope Pelczar, Marius Böttcher, Samuel Huber, Torsten Witte, Axel Finckh, Till Strowig
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 12 (2023)
IntroductionThe characterization of the influence of the microbiota on the development and drug responses during rheumatic diseases has intensified in recent years. The role of specific bacteria during disease development has become a central researc
Externí odkaz:
https://doaj.org/article/e3cd79bc37b04051bb988bdc08a0f687
Autor:
Axel Finckh, Kim Lauper, Denis Mongin, Delphine S Courvoisier, Celine Lamacchia, Diego Kyburz, Andrea Rubbert-Roth, Benoît Thomas P Gilbert, Eric Trunk, Olivia Studer, Burkhard Moeller
Publikováno v:
BMJ Open, Vol 11, Iss 7 (2021)
Purpose Rheumatoid arthritis (RA) is an insidious autoimmune disease, with an immunological onset years before diagnosis. Early interventions in preclinical stages could prevent or minimise the progression towards irreversible joint damage. The SCREE
Externí odkaz:
https://doaj.org/article/89a5518401bd4e108fe623aae311986c
Publikováno v:
Revue du Rhumatisme Monographies. 89:222-227
Publikováno v:
Joint Bone Spine. 90:105556
Publikováno v:
Annals of the rheumatic diseases.
Autor:
Axel Finckh, Kim Lauper, Denis Mongin, Delphine S Courvoisier, Benoît Thomas P Gilbert, Clémentine Perrier, Romain Aymon, Cédric Laedermann, Ruediger Mueller
Publikováno v:
BMJ Open, Vol 14, Iss 3 (2024)
Objectives This observational study compares the effectiveness of baricitinib (BARI), a targeted synthetic disease-modifying antirheumatic drug (tsDMARD), with alternative biological DMARDs (bDMARDs) in patients with rheumatoid arthritis (RA), from a
Externí odkaz:
https://doaj.org/article/70ddbb33f6b74c69b29e15f080088bd4